1-5 of 5
Bing Wu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report

Sarah E.S. Leary, Julie R. Park, Joel M. Reid, Andrew T. Ralya, Sylvain Baruchel, Bing Wu, Timothy P.L. Roberts, Xiaowei Liu, Charles G. Minard, Elizabeth Fox, Brenda Weigel, Susan Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6062–6069.
https://doi.org/10.1158/1078-0432.CCR-16-2882
Published: 12 October 2017
View article titled, Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report
Open the PDF for Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report in another window
Journal Articles

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models

Libo Zhang, Paula Marrano, Bing Wu, Sushil Kumar, Paul Thorner, Sylvain Baruchel
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2697–2708.
https://doi.org/10.1158/1078-0432.CCR-15-1853
Published: 31 May 2016
View article titled, Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
Open the PDF for Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

Sushil Kumar, Reza Bayat Mokhtari, Reihaneh Sheikh, Bing Wu, Libo Zhang, Ping Xu, Shan Man, Indhira Dias Oliveira, Herman Yeger, Robert S. Kerbel, Sylvain Baruchel
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5656–5667.
https://doi.org/10.1158/1078-0432.CCR-11-0078
Published: 01 September 2011
View article titled, Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor
Open the PDF for Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor in another window
Journal Articles

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

Steven G. DuBois, Suzanne Shusterman, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Bing Wu, Sylvain Baruchel, Julia Glade-Bender, Percy Ivy, Holcombe E. Grier, Peter C. Adamson, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5113–5122.
https://doi.org/10.1158/1078-0432.CCR-11-0237
Published: 31 July 2011
View article titled, Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study
Open the PDF for Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study in another window
Journal Articles

Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection

Xin-Rong Yang, Yang Xu, Guo-Ming Shi, Jia Fan, Jian Zhou, Yuan Ji, Hui-Chuan Sun, Shuang-Jian Qiu, Bing Yu, Qiang Gao, Yi-Zhou He, Weng-Zhen Qin, Rong-Xin Chen, Guo-Huan Yang, Bing Wu, Qing Lu, Zhi-Quan Wu, Zhao-You Tang
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3850–3859.
https://doi.org/10.1158/1078-0432.CCR-07-4338
Published: 16 June 2008
View article titled, Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection
Open the PDF for Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection in another window